Acromesomelic Dysplasia 1 Maroteaux Type C1864356
A specific form of acromesomelic dysplasia from NPR2 gene mutations. It causes severe limb shortening and short stature. Treatment is supportive.
Key facts at a glance
- ICD-10
- Q79.9
- ICD-11
- LA00.0
- Body system
- musculoskeletal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Joint pain or stiffness
(musculoskeletal)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Short stature
(musculoskeletal)Shortened forearms
(musculoskeletal)Hip dysplasia
(musculoskeletal)Scoliosis
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Physical therapy program
Customized physical therapy focusing on joint mobility, muscle strengthening, and preventing contractures through guided exercises and stretches.
Orthopedic surgical intervention
Surgical procedures to correct limb deformities, address joint abnormalities, or manage spinal complications when conservative measures are insufficient.
Additional treatment options
Regular orthopedic and endocrine monitoring
Comprehensive monitoring of growth patterns, joint function, and endocrine status through scheduled evaluations and imaging studies.
monitoringAssistive devices and adaptive equipment
Provision of supportive devices such as orthotics, walking aids, or adaptive equipment to enhance mobility and independence in daily activities.
lifestylePsychological support and counseling
Mental health support to address body image concerns, social challenges, and emotional well-being associated with living with a rare skeletal condition.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Acromesomelic Dysplasia 1 Maroteaux Type C1864356?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kantaputra PN, Intach N. Acromesomelic dysplasia Maroteaux type: clinical and molecular review. Orphanet J Rare Dis. 2022.
International Skeletal Dysplasia Consortium. Guidelines for diagnosis and management of skeletal dysplasias. Am J Med Genet A. 2020.
Vasiljevic A,enter D, Klajn A. Novel NPR2 mutations in acromesomelic dysplasia type Maroteaux. Bone. 2021.
Baujat G, Le Merrer M. Skeletal dysplasia and genetic disorders of stature: a systematic review. Lancet Diabetes Endocrinol. 2023.
Medication Comparisons
Compare medications used to treat Acromesomelic Dysplasia 1 Maroteaux Type C1864356. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy